Lamellar Revenue and Competitors
Estimated Revenue & Valuation
- Lamellar's estimated annual revenue is currently $930k per year.
- Lamellar's estimated revenue per employee is $155,000
Employee Data
- Lamellar has 6 Employees.
- Lamellar grew their employee count by -33% last year.
Lamellar's People
Name | Title | Email/Phone |
---|
Lamellar Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $9.1M | 72 | -29% | N/A | N/A |
What Is Lamellar?
Lamellar Biomedical is an innovative biotechnology company developing our proprietary LAMELLASOMEâ„¢ based therapies to transform the treatment of complex and rare lung disorders, either as biologically active products in their own right or by delivering active payloads. Along with our in-house research and development team, we are collaborating with world-renowned institutions and universities to develop therapeutics that capitalise on the unique properties of LAMELLASOMEâ„¢ formulations that protect lung tissues. Lamellar's lead products are: IPF-Lamellasome: abates pulmonary fibrosis by reducing both myofibroblasts and collagen production. IPF-Lamellasome has the potential to become the first line therapy and the new standard of care in the treatment of Idiopathic Pulmonary Fibrosis (IPF) IPF. Muco-ease: increases the fluidity of thickened human mucus and may slow disease progression in mild and moderate Cystic Fibrosis (CF) by improving mucociliary clearance Lamellasome treatment for COVID-19 intended to prevent or mitigate progression of respiratory symptoms to pneumonitis and ARDS, promoting survival ad potentially protecting lungs from fibrotic sequelae of survivors These therapies are based on LAMELLASOMEâ„¢ therapies' abilities to: Reduce inflammatory responses in pulmonary tissue. Interrupt the onset and progression of pulmonary inflammation, pneumonitis and the development of fibrosis. Modulate tissue surface tension, moisture retention and lubrication.
keywords:N/AN/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lamellar News
... boosts expression of lamellar pro-inflammatory cytokines that activate ... and alters glucose metabolism within the hoof lamellae.
To report the clinical, visual, and safety outcomes of 27 gauge pars plana vitrectomy (27G PPV) in eyes with full thickness and lamellar...
It is considered that the lamellar magnetism is responsible for the ... ilmenite lamellae and the antiferromagnetic titanohematite host.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.4M | 31 | 41% | $12M |